Pharmaseal has secured its first medical device customer – a US-based ultrasound technology company.
The Engility trial management platform was chosen following review of several clinical trial management systems (CTMS). Engility was reportedly selected for its combined CTMS and electronic trial master file (eTMF) capabilities.
The integrated platform is aimed to provide users with a higher level of productivity by allowing clinical teams to operate with one single system. Pharmaseal claims it saves time on setup, implementation, user training and validation, allowing for a better and more integrated workflow and a consistent user experience across both capabilities.
Daljit Cheema, founder and CEO of Pharmaseal, commented: “This news is a great start to the year for Pharmaseal and we are delighted Engility has been selected and licensed to support its first medical device customer to improve the management and control of their device trials.
“Furthermore, this will allow us to work with more global medical device companies who have expressed an interest in Engility allowing for smarter management and execution of medical device clinical trials.”
Daljit further commented: “We have the vision to create smarter technologies for the improvement of human health and we are excited to see what possibilities emerge from this collaboration for transforming the future of healthcare.”
